Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.47 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.47 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.47 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.47 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.47 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.47 |
| ▸ | CTPS1 | P17812 | 2/20 | 0.46 |
| ▸ | ABL1 | P00519 | 1/20 | 0.44 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6707340 | 0.91 | L3MBTL1 (0.51) | L3MBTL1POLBHDAC3HDAC4HDAC1 | |
| SCHEMBL9660491 | 0.87 | L3MBTL1 (0.45) | L3MBTL1POLBHDAC3HDAC4HDAC1 | |
| SCHEMBL6570711 | 0.85 | HDAC3 (0.44) | L3MBTL1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL28305561 | 0.84 | L3MBTL1 (0.57) | L3MBTL1POLBHDAC3HDAC4HDAC1 | |
| SCHEMBL5929882 | 0.83 | CYP1A2 (0.44) | L3MBTL1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL30889074 | 0.83 | L3MBTL1 (0.57) | L3MBTL1POLBHDAC3HDAC4HDAC1 | |
| SCHEMBL9658229 | 0.82 | MAPT (0.46) | L3MBTL1POLBHDAC3HDAC4HDAC1 | |
| SCHEMBL9658218 | 0.82 | MAPT (0.46) | L3MBTL1POLBHDAC3HDAC4HDAC1 | |
| SCHEMBL31559977 | 0.79 | L3MBTL1 (0.51) | L3MBTL1POLBHDAC3HDAC4HDAC1 | |
| SCHEMBL9660925 | 0.78 | GAA (0.65) | L3MBTL1POLBHDAC3HDAC4HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7727997-B2 | N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives | ELAN PHARMACEUTICALS, INC. (US) | 2010-06-01 | — | — | US | claimed |
| US-7354943-B2 | Statine derivatives for the treatment of Alzheimer's disease | PHARMACIA & UPJOHN (US) | 2008-04-08 | — | — | US | claimed |
| US-20070213316-A1 | Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease | ELAN PHARMACEUTICALS, INC. | 2007-09-13 | — | — | US | claimed |
| US-20050165069-A1 | Statine derivatives for the treatment of Alzheimer's disease | ALZHEIMER'S COLLABORATION | 2005-07-28 | — | — | US | claimed |
| US-20050159459-A1 | Statine derivatives for the treatment of Alzheimer's disease | ALZHEIMER'S COLLABORATION | 2005-07-21 | — | — | US | claimed |
| EP-1453789-A2 | N,N'-SUBSTITUTED-1,3-DIAMINO-2-HYDROXYPROPANE DERIVATIVES | Elan Pharmaceuticals, Inc. (US) | 2004-09-08 | — | — | EP | claimed |
| US-20040171881-A1 | N,N'-substituted-1,3-diamino-2-hydroxypropane derivatives | PHARMACIA & UPJOHN COMPANY | 2004-09-02 | — | — | US | claimed |
| EP-1404328-A1 | ALPHA-HYDROXYAMIDE STATINE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE | Elan Pharmaceuticals, Inc. (US) | 2004-04-07 | — | — | EP | claimed |
| WO-2003040096-A2 | N, N'-SUBSTITUTED-1,3-DIAMINO-2-HYDROXYPROPANE DERIVATIVES | ELAN PHARMACEUTICALS, INC. (US) | 2003-05-15 | — | — | WO | claimed |
| US-20030083356-A1 | Statine derivatives for the treatment of Alzheimer's disease | PHARMACIA & UPJOHN | 2003-05-01 | — | — | US | claimed |
| WO-2003006021-A1 | ALPHA-HYDROXYAMIDE STATINE DERIVATIVES FOR THE TREATMENT OF ALZH EIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2003-01-23 | — | — | WO | claimed |
| EP-4590666-A1 | THIAZOLE DERIVATIVES AS TAU AGGREGATION INHIBITORS | WisTa Laboratories Ltd. (SG) | 2025-07-30 | — | — | EP | disclosed |
| CN-119894874-A | Thiazole derivatives as TAU aggregation inhibitors | 维斯塔实验室有限公司 | 2025-04-25 | — | — | CN | disclosed |
| WO-2024061658-A1 | THIAZOLE DERIVATIVES AS TAU AGGREGATION INHIBITORS | WISTA LABORATORIES LTD. (SG) | 2024-03-28 | — | — | WO | disclosed |
| WO-2024043741-A1 | AUTOTAXIN INHIBITOR COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | 주식회사 레고켐 바이오사이언스 | 2024-02-29 | — | — | WO | disclosed |
| US-20030083353-A1 | Diaminediols for the treatment of Alzheimer's disease | PHARMACIA & UPJOHN | 2003-05-01 | — | — | US | disclosed |
| WO-2003006013-A1 | DIAMINEDIOLS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2003-01-23 | — | — | WO | disclosed |
| WO-2003006021-A1 | ALPHA-HYDROXYAMIDE STATINE DERIVATIVES FOR THE TREATMENT OF ALZH EIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2003-01-23 | — | — | WO | disclosed |
| WO-2002100410-A1 | METHODS OF TREATING ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2002-12-19 | — | — | WO | disclosed |
| WO-2002094768-A2 | AZA HYDROXYLATED ETHYL AMINE COMPOUNDS | ELAN PHARMACEUTICALS, INC. (US) | 2002-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050165069-A1 | Statine derivatives for the treatment of Alzheimer's disease | BACE1, APP, BACE2 | L3MBTL1 3813/4885POLB 2521/4885HDAC3 1770/4885 |
| US-20030083353-A1 | Diaminediols for the treatment of Alzheimer's disease | BACE1, APP, BACE2 | L3MBTL1 3689/4885POLB 353/4885HDAC3 3151/4885 |
| US-20050159459-A1 | Statine derivatives for the treatment of Alzheimer's disease | BACE1, APP, BACE2 | L3MBTL1 3813/4885POLB 2521/4885HDAC3 1770/4885 |
| US-20040171881-A1 | N,N'-substituted-1,3-diamino-2-hydroxypropane derivatives | BACE1, BACE2, PSEN1 | L3MBTL1 2946/4885POLB 747/4885HDAC3 956/4885 |
| US-20030083356-A1 | Statine derivatives for the treatment of Alzheimer's disease | BACE1, APP, BACE2 | L3MBTL1 3728/4885POLB 2698/4885HDAC3 1966/4885 |
| US-20070213316-A1 | Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease | BACE1, BACE2, APP | L3MBTL1 1672/4885POLB 2249/4885HDAC3 527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.